
-
Sutro Biopharma NasdaqGM:STRO Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Location: 111 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.sutrobio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-151.6M
Cash
249M
Avg Qtr Burn
-48.67M
Short % of Float
10.42%
Insider Ownership
4.58%
Institutional Own.
71.02%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Platinum-resistant ovarian cancer | Phase 3 Data readout | |
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Acute myeloid leukemia | Phase 2/3 Update | |
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) + bevacizumab Details Ovarian cancer, Cancer, Endometrial cancer | Phase 1b Update | |
M1231 (MUC1-EGFR Bispecific ADC) Details Solid tumor/s, Esophageal cancer, Non-small cell lung carcinoma, Cancer | Failed Discontinued | |
STRO-001 (BN301) (CD74-Targeting ADC) Details Cancer, B-cell lymphoma, Follicular lymphoma, Lymphoma, Mantle cell lymphoma | Failed Discontinued |